Ocular Involvement in Systemic Sclerosis: Updated Review and New Insights on Microvascular Impairment

References

• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
   PubMed Web of Science ®Google Scholar
• Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity. 2005;38(2):113–116. doi:10.1080/16066350500095415.
   PubMed Web of Science ®Google Scholar
• Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M. Scleroderma: From Pathogenesis to Comprehensive Management. New York: Springer; 2016:1–689.
   Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. doi:10.1136/ard.2009.114264.
   PubMed Web of Science ®Google Scholar
• Kucharz EJ, Kopec-Medrek M. Systemic sclerosis sine scleroderma. Adv Clin Exp Med. 2017;26(5):875–880. doi:10.17219/acem/64334.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902–3912. doi:10.1002/art.24038.
   PubMed Web of Science ®Google Scholar
• Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12):2087–2093. doi:10.1136/annrheumdis-2013-203716.
   PubMed Web of Science ®Google Scholar
• Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis. 2011;70(3):476–481. doi:10.1136/ard.2010.136929.
   PubMed Web of Science ®Google Scholar
• Horimoto AMC, de Macedo Possamai V, da Costa IP. Sjögren’s syndrome and sicca symptoms in patients with systemic sclerosis. J Arthritis. 2016;5:2.
   Google Scholar
• Hekimsoy V, Kaya EB, Akdogan A, et al. Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients. Int J Cardiovasc Imaging. 2018;34:883–892. doi:10.1007/s10554-018-1299-z.
   PubMed Web of Science ®Google Scholar
• Matucci‐Cerinic M, Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–1962. doi:10.1002/art.37988.
   PubMed Web of Science ®Google Scholar
• Farkas TG, Sylvester V, Archer D. The choroidopathy of progressive systemic sclerosis (scleroderma). Am J Ophthalmol. 1972;74(5):875–86. doi:10.1016/0002-9394(72)91208-1.
   PubMed Web of Science ®Google Scholar
• Gomes Bde A, Santhiago MR, Magalhaes P, Kara-Junior N, Azevedo MN, Moraes HV Jr. Ocular findings in patients with systemic sclerosis. Clinics (Sao Paulo). 2011;66(3):379–385. doi:10.1590/s1807-59322011000300003.
   PubMed Web of Science ®Google Scholar
• Ushiyama O, Ushiyama K, Yamada T, et al. Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns. Ann Rheum Dis. 2003;62(3):204–207. doi:10.1136/ard.62.3.204.
   PubMed Web of Science ®Google Scholar
• Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis–associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 2006;54(7):2243–2249. doi:10.1002/art.21922.
   PubMed Web of Science ®Google Scholar
• Kök M, Ayan A, Küçük MF, Erol MK, Yaprak L. Evaluation of the direct effects on retinal and choroidal microvascularity of systemic scleroderma. Microvasc Res. 2021;136:104166. doi:10.1016/j.mvr.2021.104166.
   PubMed Web of Science ®Google Scholar
• Kreps EO, Carton C, Cutolo M, et al. Ocular involvement in systemic sclerosis: a systematic literature review, it’s not all scleroderma that meets the eye. Semin Arthritis Rheum. 2019;49(1):119–125. doi:10.1016/j.semarthrit.2018.12.007.
   Web of Science ®Google Scholar
• Luo X, Shen Y-M, Jiang M-N, Lou X-F, Shen Y. Ocular blood flow autoregulation mechanisms and methods. J Ophthalmol. 2015;2015:864–871.
   Web of Science ®Google Scholar
• Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunol Res. 2017;65:790–797. doi:10.1007/s12026-017-8926-y.
   PubMed Web of Science ®Google Scholar
• Skaug B, Assassi S. Type I interferon dysregulation in systemic sclerosis. Cytokine. 2020;132:154635. doi:10.1016/j.cyto.2018.12.018.
   PubMed Web of Science ®Google Scholar
• Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 2008;58(4):1165–1174. doi:10.1002/art.23406.
   PubMedGoogle Scholar
• Slobodin G, Rimar D. Regulatory T cells in systemic sclerosis: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(2):194–201. doi:10.1007/s12016-016-8563-6.
   PubMed Web of Science ®Google Scholar
• MacDonald KG, Dawson NAJ, Huang Q, Dunne JV, Levings MK, Broady R. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol. 2015;135(4):946–955 e9. doi:10.1016/j.jaci.2014.12.1932.
   PubMed Web of Science ®Google Scholar
• Zebryk P, Puszczewicz M. [Autoantibodies in systemic sclerosis]. Postepy Hig Med Dosw (Online). 2015;69:654–660. Autoprzeciwciala w twardzinie ukladowej. doi:10.5604/17322693.1154085.
   PubMedGoogle Scholar
• Grasshoff H, Fourlakis K, Comduhr S, Riemekasten G. Autoantibodies as biomarker and therapeutic target in systemic sclerosis. Biomedicines. 2022;10(9). doi:10.3390/biomedicines10092150.
   PubMed Web of Science ®Google Scholar
• Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70(3):530–536. doi:10.1136/ard.2010.135772.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum. 2007;56(6):21023; author reply 2103–2104. doi:10.1002/art.22636.
   Google Scholar
• Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15(7):753–764. doi:10.1080/1744666X.2019.1614915.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578–87. doi:10.1038/nrrheum.2010.104.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;8(1):42–54. doi:10.1038/nrrheum.2011.149.
   PubMed Web of Science ®Google Scholar
• Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev. 2017;16(8):774–786. doi:10.1016/j.autrev.2017.05.024.
   PubMed Web of Science ®Google Scholar
• Bruni C, Frech T, Manetti M, et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front Immunol. 2018;9:2045. doi:10.3389/fimmu.2018.02045.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases. Physiol Rev. 2019;99(2):1281–1324. doi:10.1152/physrev.00021.2018.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Di Benedetto P, Ruscitti P, et al. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther. 2014;16(5):442. doi:10.1186/s13075-014-0442-z.
   PubMed Web of Science ®Google Scholar
• Manetti M. Deciphering the alternatively activated (M2) phenotype of macrophages in scleroderma. Exp Dermatol. 2015;24(8):576–8. doi:10.1111/exd.12727.
   PubMed Web of Science ®Google Scholar
• Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186–195. doi:10.1111/imm.12910.
   PubMed Web of Science ®Google Scholar
• Christmann RB, Lafyatis R. The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther. 2010;12(5):146. doi:10.1186/ar3167.
   PubMed Web of Science ®Google Scholar
• West RH, Barnett AJ. Ocular involvement in scleroderma. Br J Ophthalmol. 1979;63(12):845–847. doi:10.1136/bjo.63.12.845.
   PubMed Web of Science ®Google Scholar
• Szucs G, Szekanecz Z, Aszalos Z, et al. A wide spectrum of ocular manifestations signify patients with systemic sclerosis. Ocul Immunol Inflamm. 2021;29(1):81–89. doi:10.1080/09273948.2019.1657467.
   PubMed Web of Science ®Google Scholar
• Ratiglia R, Scorza R, Santori M, et al. Ocular disorders in systemic scleroderma. Ophtalmologie. 1987;1:527–529.
   PubMedGoogle Scholar
• Sahin Atik S, Koc F, Akin Sari S, Sefi Yurdakul N, Ozmen M, Akar S. Anterior segment parameters and eyelids in systemic sclerosis. Int Ophthalmol. 2016;36(4):577–583. doi:10.1007/s10792-015-0165-4.
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010;51(12):6125–6130. doi:10.1167/iovs.10-5390.
   PubMed Web of Science ®Google Scholar
• Rentka A, Nagy A, Harsfalvi J, et al. Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. Rheumatol Int. 2017;37:1835–1845. doi:10.1007/s00296-017-3794-2.
   PubMed Web of Science ®Google Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/jop.2019.0060.
   PubMed Web of Science ®Google Scholar
• Rentka A, Harsfalvi J, Berta A, et al. Vascular endothelial growth factor in tear samples of patients with systemic sclerosis. Mediators Inflamm. 2015;2015:573681. doi:10.1155/2015/573681.
   PubMed Web of Science ®Google Scholar
• Waszczykowska A, Gos R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P. Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci. 2013;9(6):1107–1113. doi:10.5114/aoms.2013.39217.
   PubMed Web of Science ®Google Scholar
• Mancel E, Janin A, Gosset D, Hatron PY, Gosselin B. Conjunctival biopsy in scleroderma and primary Sjogren’s syndrome. Am J Ophthalmol. 1993;115(6):792–799. doi:10.1016/s0002-9394(14)73650-5.
   PubMed Web of Science ®Google Scholar
• Hugle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor beta in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–799. doi:10.1002/art.30190.
   PubMedGoogle Scholar
• Gagliano C, Visalli E, Toro MD, et al. Dry eye in systemic sclerosis patients: novel methods to monitor disease activity. Diagnostics. 2020;10(6):404. doi:10.3390/diagnostics10060404.
   Web of Science ®Google Scholar
• Ihanamaki T, Pelliniemi LJ, Vuorio E. Collagens and collagen-related matrix components in the human and mouse eye. Prog Retin Eye Res. 2004;23(4):403–34. doi:10.1016/j.preteyeres.2004.04.002.
   PubMed Web of Science ®Google Scholar
• Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis–a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014;10(7):390–402. doi:10.1038/nrrheum.2014.53.
   PubMed Web of Science ®Google Scholar
• Serup L, Serup J, Hagdrup HK. Increased central cornea thickness in systemic sclerosis. Acta Ophthalmol (Copenh). 1984;62(1):69–74. doi:10.1111/j.1755-3768.1984.tb06758.x.
   PubMed Web of Science ®Google Scholar
• Gomes Bde A, Santhiago MR, Kara-Junior N, Noe RA, de Azevedo MN, Moraes HV Jr. Central corneal thickness in patients with systemic sclerosis: a controlled study. Cornea. 2011;30(10):1125–1128. doi:10.1097/ICO.0b013e318206cac1.
   PubMed Web of Science ®Google Scholar
• Gomes BF, Santhiago MR, Gomes SF, Kara-Junior N, Moraes HV Jr. Longitudinal evaluation of central corneal thickness in patients with systemic sclerosis. Cornea. 2016;35(12):1584–1588. doi:10.1097/ICO.0000000000000950.
   PubMed Web of Science ®Google Scholar
• Emre S, Kayikcioglu O, Ates H, et al. Corneal hysteresis, corneal resistance factor, and intraocular pressure measurement in patients with scleroderma using the reichert ocular response analyzer. Cornea. 2010;29(6):628–631. doi:10.1097/ICO.0b013e3181c3306a.
   PubMed Web of Science ®Google Scholar
• Sahin M, Yuksel H, Sahin A, et al. Evaluation of the anterior segment parameters of the patients with scleroderma. Ocul Immunol Inflamm. 2017;25(2):233–238. doi:10.3109/09273948.2015.1115079.
   PubMed Web of Science ®Google Scholar
• Nagy A, Rentka A, Nemeth G, et al. Corneal manifestations of systemic sclerosis. Ocul Immunol Inflamm. 2019;27(6):968–977. doi:10.1080/09273948.2018.1489556.
   PubMed Web of Science ®Google Scholar
• Kahaleh B, Matucci-Cerinic M. Raynaud’s phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum. 1995;38(1):1–4. doi:10.1002/art.1780380102.
   PubMedGoogle Scholar
• Cerinic MM, Generini S, Pignone A, Casale R. The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. Rheum Dis Clin North Am. 1996;22(4):879–892. doi:10.1016/s0889-857x(05)70306-9.
   PubMed Web of Science ®Google Scholar
• Bertinotti L, Pietrini U, Del Rosso A, et al. The use of pupillometry in joint and connective tissue diseases. Ann N Y Acad Sci. 2002;966(1):446–55. doi:10.1111/j.1749-6632.2002.tb04246.x.
   PubMedGoogle Scholar
• Del Rosso A, Bertinotti L, Pietrini U, et al. Pupillocynetic activity of substance P in systemic sclerosis. J Rheumatol. 2003;30(6):1231–1237.
   PubMed Web of Science ®Google Scholar
• Kozikowska M, Luboń W, Kucharz E, Mrukwa-Kominek E. Ocular manifestations in patients with systemic sclerosis. Reumatologia/Rheumatology. 2020;58(6):401–406. doi:10.5114/reum.2020.102004.
   Google Scholar
• Aissopou EK, Bournia VK, Protogerou AD, et al. Intact calibers of retinal vessels in patients with systemic sclerosis. J Rheumatol. 2015;42(4):608–613. doi:10.3899/jrheum.141425.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879–889. doi:10.1038/nri1224.
   PubMed Web of Science ®Google Scholar
• Kirkham T. Scleroderma and Sjögren’s syndrome. Br J Ophthalmol. 1969;53(2):131. doi:10.1136/bjo.53.2.131.
   PubMed Web of Science ®Google Scholar
• Cheung CY, Zheng Y, Hsu W, et al. Retinal vascular tortuosity, blood pressure, and cardiovascular risk factors. Ophthalmology. 2011;118(5):812–818. doi:10.1016/j.ophtha.2010.08.045.
   PubMed Web of Science ®Google Scholar
• Maclean H, Guthrie W. Retinopathy in scleroderma. Trans Ophthalmol Soc U K. 1970;89:209–220.
   PubMedGoogle Scholar
• Serup L, Serup J, Hagdrup H. Fundus fluorescein angiography in generalized scleroderma. Ophthalmic Res. 1987;19(5):303–308. doi:10.1159/000265512.
   PubMed Web of Science ®Google Scholar
• Grennan DM, Forrester J. Involvement of the eye in SLE and scleroderma. A study using fluorescein angiography in addition to clinical ophthalmic assessment. Ann Rheum Dis. 1977;36(2):152–156. doi:10.1136/ard.36.2.152.
   PubMed Web of Science ®Google Scholar
• Abdellatief A, Balasubramaniam SC, Grube TJ, Gonzalez Santiago TM, Osborn TG, Pulido JS. Indocyanine green angiographic evidence of choroiditis in scleroderma. Retin Cases Brief Rep Summer, 2015;9(3);231–234. doi:10.1097/ICB.0000000000000146.
   PubMedGoogle Scholar
• Milenkovic S, Petrovic L, Risimic D, et al. Choroidal sclerosis in localized scleroderma (morphea en plaque). Ophthalmic Res. 2008;40(2):101–104. doi:10.1159/000113889.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Gualtierotti R, Pierro L, et al. Choroidal impairment and macular thinning in patients with systemic sclerosis: the acute study. Microvasc Res. 2015;97:31–36. doi:10.1016/j.mvr.2014.08.008.
   PubMed Web of Science ®Google Scholar
• Esen E, Tas DA, Sizmaz S, Turk I, Unal I, Demircan N. Evaluating choroidal characteristics in systemic sclerosis using enhanced depth imaging optical coherence tomography. Ocul Immunol Inflamm. 2017;25(3):356–362. doi:10.3109/09273948.2015.1129424.
   PubMed Web of Science ®Google Scholar
• Coskun E, Zengin O, Kenan S, et al. Evaluation of choroidal thickness in patients with scleroderma. Eye (Lond). 2016;30(4):588–592. doi:10.1038/eye.2015.287.
   PubMed Web of Science ®Google Scholar
• Ranjbar M, Rothe M, Klapa S, et al. Evaluation of choroidal substructure perfusion in patients affected by systemic sclerosis: an optical coherence tomography angiography study. Scand J Rheumatol. 2020;49(2):141–145. doi:10.1080/03009742.2019.1641616.
   PubMed Web of Science ®Google Scholar
• Kilinc Hekimsoy H, Sekeroglu MA, Kocer AM, Akdogan A. Analysis of retinal and choroidal microvasculature in systemic sclerosis: an optical coherence tomography angiography study. Eye (Lond). 2020;34(4):763–770. doi:10.1038/s41433-019-0591-z.
   PubMed Web of Science ®Google Scholar
• Rommel F, Prangel D, Prasuhn M, Grisanti S, Ranjbar M. Correlation of retinal and choroidal microvascular impairment in systemic sclerosis. Orphanet J Rare Dis. 2021;16(1):27. doi:10.1186/s13023-020-01649-5.
   PubMed Web of Science ®Google Scholar
• Rothe M, Rommel F, Klapa S, et al. Evaluation of retinal microvascular perfusion in systemic sclerosis: a case-control study. Ann Rheum Dis. 2019;78(6):857–858. doi:10.1136/annrheumdis-2018-214541.
   PubMed Web of Science ®Google Scholar
• Carnevali A, Giannaccare G, Gatti V, et al. Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study. Rheumatology (Oxford). 2021;60(12):5827–5832. doi:10.1093/rheumatology/keab258.
   PubMed Web of Science ®Google Scholar
• Fang X, Yu S, Peng Y, et al. The function of retinal thickness and microvascular alterations in the diagnosis of systemic sclerosis. Biomed Res Int. 2023;2023:1–10. doi:10.1155/2023/1805938.
   Web of Science ®Google Scholar
• Mihailovic N, Lahme L, Braasch S, et al. Altered ocular microvasculature in patients with systemic sclerosis and very early disease of systemic sclerosis using optical coherence tomography angiography. Sci Rep. 2022;12(1):10990. doi:10.1038/s41598-022-14377-6.
   PubMed Web of Science ®Google Scholar
• Sha M, Griffin M, Denton CP, Butler PE. Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosis. Microvasc Res. 2019;126:103890. doi:10.1016/j.mvr.2019.103890.
   PubMed Web of Science ®Google Scholar
• Erturk A, Erogul O, Kasikci M. Optical coherence tomography angiography is a useful tool for distinguishing primary Raynaud’s phenomenon from systemic sclerosis and/or very early disease of systemic sclerosis. Diagnostics (Basel). 2023;13(15):2607. doi:10.3390/diagnostics13152607.
   PubMedGoogle Scholar
• Allanore Y, Parc C, Monnet D, Brezin AP, Kahan A. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis. 2004;63(10):1276–1278. doi:10.1136/ard.2003.013540.
   PubMed Web of Science ®Google Scholar
• Chan AY, Liu DT. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis. 2005;64:341–2; author reply 342.
   PubMed Web of Science ®Google Scholar